Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed.
Clinical impact of [Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Olga BraginaDepartment of Nuclear Therapy and Diagnostic, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634050 Tomsk, Russia.
Vladimir ChernovDepartment of Nuclear Therapy and Diagnostic, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634050 Tomsk, Russia.
Mariia LarkinaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0003-1176-2441
Ruslan VarvashenyaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.
Roman ZelchanDepartment of Nuclear Therapy and Diagnostic, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634050 Tomsk, Russia.
Anna MedvedevaDepartment of Nuclear Therapy and Diagnostic, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634050 Tomsk, Russia.
Anastasiya IvanovaDepartment of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.ORCID 0009-0009-3775-9989
Liubov TashirevaDepartment of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.ORCID 0000-0003-2061-8417
Panagiotis KanellopoulosDepartment of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.ORCID 0000-0002-0617-3936
Jens SörensenRadiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0001-5738-9983
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.ORCID 0000-0001-6120-2683
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden.ORCID 0000-0002-6122-1734
Funding
Prostatacancerfonden PKSwedish Cancer Society 23 2645 PjF 01HSwedish Cancer Society 24 3523 PjSwedish Research Council 2022 - 00556Swedish Research Council 2023-02158
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
breast cancergastrin-releasing peptide receptor antagonistoptimal injected massradionuclide molecular imagingSPECT
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [ · full record | OpenQuestion